ArticleProbiotics and antimicrobial proteins2026
Exploring the Activity of Bacteriocins Against Bacterial Biofilms Using a Simple and Inexpensive Assay.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
There is an urgent need for novel antimicrobials that can combat antibiotic resistant bacteria. Biofilms constitute a particular niche where bacteria display an intrinsic higher resistance to antibiotics and that favors resistance appearance and spread among species. However, the susceptibility tests for sessile bacteria are not well standardized. This work provides a high-throughput, affordable and simple methodology to grow biofilms on a three-dimensional surface represented by glass beads placed in 96-well microtiter plates. Two Gram-positive and two Gram-negative bacterial species were tested. Biofilms showed the highest cell number after 48-h or 72-h incubation, depending on the bacterial species, using brain heart infusion, and typical biofilms were observed by electron microscopy. It has been benchmarked with the commonly used Calgary Biofilm device proving similar adhesion properties and susceptibility to ampicillin, erythromycin, vancomycin, ciprofloxacin, kanamycin, and gentamicin. Bacteriocins are potent antimicrobial peptides produced by bacteria with promising properties for clinical use but poorly studied against biofilms. Thus, upon biofilm formation optimization, the bacteriocins nisin and the enterocin AS-48 have been purified and used against Gram-positive species biofilms showing a mild increase, below tenfold, in the bactericidal concentration compared to planktonic cells. Remarkably, due to the ability of pore formation in the cell membrane, these bacteriocins were able to provide an eradication concentration of 500 mg/L of nisin and 25 mg/L of AS-48 for Enterococcus faecalis and 83.3 mg/L of nisin and 18.5 mg/L of AS-48 for Staphylococcus aureus. These data highlight the value of bacteriocins as novel antimicrobial agents for further therapeutic development.
Indexed as
Identifiers
41004020What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.